European Psychiatry - Volume 41 - April 2017

395 / 916

25th European congress of psychiatry / European Psychiatry 41S (2017) S365–S404 S391
8 University of South Australia, Department of Rural Health, Whyalla,
Australia
9 Hamad Medical Corporation, Health Services and Population
Research Centre, Doha, Qatar
∗ Corresponding author.
Introduction Annual monitoring of physical health of peoplewith
severe mental illness (SMI) in primary or secondary care is recom-
mended in England.
Objective The SMI Health Improvement Profile (HIP) was devel-
oped to target physical well-being in SMI through the role of the
mental health nurse.
Aim The primary aim was to investigate if health checks per-
formed by community mental health nurses (CMHNs) trained to
use the HIP improved the physical well-being of patients with SMI
at 12 months.
Methods A single blind, parallel group randomised controlled
trial of training to use the HIP (clustered at the level of the nurse).
Physical well-beingwasmeasured in study patients using the phys-
ical component score of the SF36v2 at baseline and at 12 months.
Results Sixty CMHNs (working with 173 patients) were assigned
to the HIP programme (training to use the HIP) or treatment as
usual. The HIP was completed with 38 (42%) patients at baseline
and 22 (24%) at follow-up in the HIP programme group. No effect
of the HIP programme on physical health-related quality of life of
study patients was identified, a finding supported by per protocol
analyses.
Conclusions This study found no evidence that CMHN delivered
health checks following training to use the HIP are effective at
improving the physical well-being of SMI patients at one year. More
attention to methods that aim to enable the delivery, receipt and
enactment of evidence-based interventions to improve physical
health outcomes in this population is urgently required.
ISRCTN: 41137900.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
EW0826
Brainstem audiometry as a diagnostic
tool in psychiatry: Preliminary results
from a blinded study
V. Wahlström , R. Wynn ∗
1 Balsfjord General Practitioner’s Office, Balsfjord, Norway
2 UiT The Arctic University of Norway, Department of Clinical
Medicine, Tromsø, Norway
3 University Hospital of North Norway, Division of Psychiatry and
Substance Abuse, Tromsø, Norway
∗ Corresponding author.
Background Some prior studies of brainstem audiometry have
found illness-specific aberrations, suggesting that this procedure
can be of use to clinicians in diagnosing certain psychiatric illnesses.
Aims The study aimed to examine the diagnostic properties of a
brain stem audiometry procedure (SD-BERA®) for patients suffer-
ing from schizophrenia and bipolar disorder.
Methods A blinded study including 12 patients with schizophre-
nia, 12 patients with bipolar disorder, and 12 healthy controls was
performed in 2014/2015. The patients were recruited from psy-
chiatric specialist services and a primary care office in the County
of Troms, Norway. The patients and controls were examined with
brainstem audiometry. The clinical diagnoses were not known to
the researchers who analysed the brain stem audiometry data at
the Swedish company SensoDetect. Sensitivity and specificity for
each group (compared to healthy controls) was calculated.
Results The brain stem audiometry procedure had a high degree
of sensitivity (1.00), but a lower degree of specificity (0.45) when
patients suffering from bipolar disorder were compared to healthy
controls. For the diagnosis of schizophrenia, the brain stemaudiom-
etry procedure had a high degree of specificity (0.91), but a
lower degree of sensitivity (0.33) when patients were compared
to healthy controls.
Conclusions This method may help clinicians by lending support
to a clinically suspected diagnosis of schizophrenia. The relatively
low specificity for bipolar disorder could suggest that the method
needs further development before it can be useful clinically when
the diagnosis of bipolar disorder is suspected. Further scientific
testing is needed to verify these findings.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
EW0827
Aripiprazole in treatment of disability
in social, professional and family life
in schizophrenia patients
N. Zivkovic∗, G. Djokic , D. Curcic
Psychiatric Clinic Laza Lazarevic, Emergency Psychiatry Department,
Belgrade, Serbia
∗ Corresponding author.
Introduction Enhancement of overall functioning is one of most
important goals in treatment of schizophrenia (SCH) patients.
Objective To assess efficacy of aripiprazole in treatment of dis-
ability and impairment in social, professional and family life in SCH
patients.
Methods This study included 50 patients with SCH diagnosed
by ICD-10 criteria, divided into H (Haloperidol, 5–20mg/24 h)
group (25 patients), and A (Aripiprazole, 10–30mg/24 h) group (25
patients). Antipsychotics were tested for 12 months with Positive
and Negative Symptom Schedule Scale (PANSS), Sheehan Disability
Scale (SDS) and the number of withdrawals attributed to adverse
event (AE).
Results The mean pretrial PANSS score was 103.6 in A and 105.3
inHgroup. Themean PANSS score after 12monthswas 53.5 inA and
54.4 in H group. There were no significant statistical difference in
PANSS pretrial scores and scores after 12 months between groups,
P = 0.619; P = 0.364. There were significant statistical difference in
PANSS score reduction after 12 months in both groups (P < 0.001).
Aripiprazole improved all SDS scores in comparison to Haloperidol
with high statistical significance.Work: A vs. H,P < 0.001; social life:
A vs. H, P < 0.001; family life: A vs. H, P < 0.001; days lost: A vs. H,
P = 0.012; days unproductive: A vs. H, P= 0.007; 8.0% AEs occurred
in A, and 36.0% in H group.
Conclusions Aripiprazole showed same efficacy as haloperidol in
treatment of SCH. Aripiprazole showed significantly better efficacy
in treatment of disability and impairment. Number of withdrawals
was significantly higher in haloperidol group.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
EW0828
Smoking and tardive dyskinesia in
patients with schizophrenia
L. Zouari , N. Smaoui , I. Abida , N. Charfi∗ Maâlej , N. Zouari ,
J. Ben Thabet , M. Maâlej
Hédi Chaker University Hospital, Psychiatry, Sfax, Tunisia
∗ Corresponding author.
Introduction Tardive dyskinesia (TD) is a drug-induced move-
ment disorder that arises with antipsychotics. These drugs are the
mainstay of treatment for schizophrenia. Epidemiological studies
have shown mixed results on smoking’s association with TD.